This position paper describes the concerns of some Consortium members at the apparent policy differences emerging between different United Nations agencies, and individual member states, in the run up to the annual meeting of the UN agency responsible for oversight of the global drug control system. This meeting, held in Vienna in March, runs the risk of approving positions on Harm Reduction and Afghanistan that are at odds with the available evidence of what works in reducing drug problems.